停經後骨質疏鬆症治療市場規模、佔有率和成長分析：按藥物類別、給藥途徑、分銷管道和地區分類－2026-2033年產業預測

2024 年全球停經後骨質疏鬆症治療市場價值為 145.2 億美元，預計到 2025 年將成長至 154.1 億美元，到 2033 年將成長至 248.5 億美元，在預測期（2026-2033 年）內複合年成長率為 6.12%。

全球停經後骨質疏鬆症治療市場主要受女性人口老化以及雌激素缺乏導致的骨質流失的驅動。該市場的重要性體現在脆性骨折的高發生率上，脆性骨折會導致嚴重的疾病負擔、死亡和醫療成本增加，促使保險公司和政策制定者優先考慮早期診斷和有效治療。市場格局正從傳統的口服雙磷酸鹽轉向先進的生物製藥，由於副作用減少，患者的治療效果和用藥依從性均有所提高。人工智慧的整合正在革新個人化診斷和治療，它利用影像分析和預測模型來識別風險並制定個人化治療方法。此外，篩檢系統的改進和新治療方法的湧現正在擴大治療覆蓋範圍並推動市場需求。

全球停經後骨質疏鬆症治療市場的成長要素

大眾和醫療專業人員對停經後骨質疏鬆症的認知不斷提高，顯著促進了早期診斷和積極管理，從而吸引了更多患者尋求治療。加強對醫療專業人員的教育和培訓，有助於他們更好地了解風險因素和治療益處，從而促進患者更早開始治療並堅持治療方案。隨著意識的提高，患者更加積極地參與與醫療專業人員的協作決策中，並探索各種治療選擇。這種參與度的提高推動了對藥物治療和支持性護理的持續需求，同時也刺激了對服務提供和產品創新的投資。

全球停經後骨質疏鬆症治療市場面臨的限制因素

全球停經後骨質疏鬆症治療市場面臨許多挑戰，包括治療費用飆升和保險報銷政策不一致。這些因素阻礙了患者獲得治療，妨礙了處方治療的啟動和持續，最終限制了市場成長。不斷上漲的自付費用往往迫使患者和醫療服務提供者選擇更經濟實惠的治療方案或非藥物療法，即使在臨床上適用，也會導致處方量減少。此外，支付方的限制和預先核准程序使處方流程複雜化，導致治療啟動延遲，對治療依從性和患者對治療價值的認知產生負面影響。這些經濟和製度障礙抑制了需求，減緩了創新治療方法的引入，並降低了市場成長和服務開發的獎勵。

全球停經後骨質疏鬆症治療市場趨勢

全球停經後骨質疏鬆症治療市場正日益採用個人化診療路徑，重點在於根據患者的個別情況量身訂做預防和治療策略。透過納入遺傳風險、骨質評估、現有合併症和生活方式因素，醫療專業人員可以選擇最有效的治療方法和監測方案。決策支援工具的使用和加強跨學科協作正逐漸成為標準做法，從而最佳化治療效果和療程。這一趨勢正在推動患者用藥依從性和健康結果的改善，同時也促進了臨床指南的持續改進，並提高了支付方對循證報銷實踐的認知。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球停經後骨質疏鬆症治療市場規模：依藥物類別分類

• 雙磷酸鹽類藥物
• Denosumab（RANK配體抑制劑）
• 特立帕肽/PTH類似物
• SERMs（選擇性雌激素受體調節）
• 羅莫索單抗

全球停經後骨質疏鬆症治療市場規模：依治療途徑分類

• 口服
• 注射藥物
• 靜脈

全球停經後骨質疏鬆症治療市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 線上

全球停經後骨質疏鬆症治療市場規模：依地區分類

• 北美洲
• 歐洲
• 亞太地區

全球停經後骨質疏鬆症治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Amgen Inc.（Prolia/Evenity）
• Eli Lilly（Forteo）
• UCB SA（Evenity-co-marketed）
• Pfizer Inc.
• Merck & Co.
• Novartis AG
• Radius Health
• Servier Laboratories
• Warner Chilcott
• Shire（Takeda）
• Roche
• AstraZeneca
• Gedeon Richter
• Chugai Pharmaceutical
• Kyowa Kirin

結論與建議

Global Postmenopausal Osteoporosis Treatment Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 15.41 Billion in 2025 to USD 24.85 Billion by 2033, growing at a CAGR of 6.12% during the forecast period (2026-2033).

The global postmenopausal osteoporosis treatment market is driven by the increasing aging female population and the associated bone loss due to estrogen deficiency. This market's significance is highlighted by the high incidence of fragility fractures, which lead to notable morbidity, mortality, and healthcare costs, prompting payers and policymakers to emphasize early diagnosis and effective treatment. The landscape has shifted from traditional oral bisphosphonates to advanced biologics, enhancing patient outcomes and adherence due to fewer side effects. The integration of AI is revolutionizing diagnosis and treatment personalization, leveraging image analysis and predictive modeling to identify risks and tailor therapies. This, combined with improved screening efforts and the availability of novel therapies, is expanding access and driving demand in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Postmenopausal Osteoporosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Postmenopausal Osteoporosis Treatment Market Segments Analysis

Global postmenopausal osteoporosis treatment market is segmented by drug class, route, distribution and region. Based on drug class, the market is segmented into Bisphosphonates, Denosumab (RANK Ligand Inhibitor), Teriparatide/PTH Analogs, SERMs (Selective Estrogen Receptor Modulators) and Romosozumab. Based on route, the market is segmented into Oral, Injectable and Intravenous. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Postmenopausal Osteoporosis Treatment Market

The rise in public and clinical awareness regarding postmenopausal osteoporosis significantly contributes to early diagnosis and proactive management, resulting in a larger patient base seeking treatment. Enhanced educational initiatives and training for healthcare providers lead to improved identification of risk factors and an understanding of treatment benefits, which promotes prompt initiation and adherence to therapeutic regimens. As awareness increases, patients tend to engage more in shared decision-making with their healthcare professionals and actively explore various treatment options. This heightened engagement not only drives sustained demand for both pharmacological and supportive care but also encourages investment in service delivery and product innovation.

Restraints in the Global Postmenopausal Osteoporosis Treatment Market

The Global Postmenopausal Osteoporosis Treatment market faces significant challenges due to high treatment costs and inconsistent reimbursement policies, which impede patient access and discourage both the initiation and continuation of prescribed therapies, ultimately hindering market expansion. Elevated out-of-pocket expenses often compel patients and healthcare providers to opt for more affordable or non-pharmacological management options, even when clinically indicated, leading to a decrease in prescription volumes. Additionally, payer limitations and prior authorization processes create complexities in prescribing, causing delays in therapy commencement that negatively affect treatment adherence and perceived value. These economic and systemic barriers dampen demand, slow the adoption of innovative therapies, and diminish incentives for market growth and service development.

Market Trends of the Global Postmenopausal Osteoporosis Treatment Market

The Global Postmenopausal Osteoporosis Treatment market is increasingly embracing personalized care pathways, which focus on customizing prevention and treatment strategies based on individual patient profiles. By incorporating genetic risks, assessments of bone quality, existing comorbidities, and lifestyle factors, healthcare providers are able to select the most effective therapies and monitoring protocols. The use of decision-support tools and enhanced interdisciplinary collaboration is becoming standard practice, optimizing both treatment efficacy and duration. This trend fosters improved patient adherence and health outcomes, while prompting ongoing refinements in clinical guidelines and encouraging payer recognition of evidence-based reimbursement practices.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Postmenopausal Osteoporosis Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Bisphosphonates
• Denosumab (RANK Ligand Inhibitor)
• Teriparatide/PTH Analogs
• SERMs (Selective Estrogen Receptor Modulators)
• Romosozumab

Global Postmenopausal Osteoporosis Treatment Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Intravenous

Global Postmenopausal Osteoporosis Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Postmenopausal Osteoporosis Treatment Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Postmenopausal Osteoporosis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Route, Distribution, Region)
  • US
  • Canada
• Europe (Drug Class, Route, Distribution, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route, Distribution, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route, Distribution, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route, Distribution, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (Prolia/Evenity)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Forteo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA (Evenity - co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radius Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Warner Chilcott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Takeda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations